834. Risk Factors Associated with the Development of Linezolid Non-susceptible Vancomycin-Resistant Enterococcus faecium
Session: Poster Abstract Session: Bacteremia and Endocarditis
Friday, October 9, 2015
Room: Poster Hall
  • IDWeek_2015_Ver5.pdf (171.8 kB)
  • Background: Linezolid is a mainstay in the treatment of vancomycin-resistant enterococcal (VRE) infections. The widespread clinical success of linezolid has been tempered by descriptions of linezolid-non-susceptible VRE (LNVRE). We sought to determine the risk factors associated with the development of LNVRE bacteremia.

    Methods: We conducted a case-control study of patients with VRE bacteremia from 9/1/2007 to 12/31/2014 admitted to The Johns Hopkins Hospital. Cases were patients with VRE bacteremia resistant or intermediate to linezolid (LNVRE). Cases were matched 1:2 to bacteremic patients with linezolid-susceptible VRE isolates (LSVRE) by year of positive blood culture. Cases and controls were compared using Chi-square and Wilcoxon rank sum tests. Independent risk factors for LNVRE bacteremia were identified using logistic regression.

    Results: 102 unique patients with VRE bacteremia were identified. Thirty-four LNVRE cases were matched to 68 LSVRE controls. Baseline characteristics were similar between groups with the exceptions of more LNVRE patients having solid organ transplant (26% v. 18%; p = 0.05), hematopoietic stem cell transplant (21% vs 7%; p = 0.05) or recent surgery (50% vs. 28%; p = 0.03). Most episodes of VRE bacteremia had a central line or intra-abdominal source, with intra-abdominal source being higher in the LNVRE group (41% v. 18%, p = 0.01). Logistic regression revealed that recent exposure to linezolid (OR = 18.45, p = <0.01) and meropenem (OR = 3.46, p = 0.03) were associated with development of LNVRE bacteremia. Seven out of 19 patients with LNVRE bacteremia were exposed to linezolid for inappropriate indications such as VRE colonization of stool, urine, respiratory tract or drains.

    Conclusion: LNVRE bacteremia was strongly associated with prior linezolid use. While often unavoidable in ill patients with VRE infections, the necessity of linezolid use should be critically evaluated in all patients receiving this agent.

    Tiffeny Smith, PharmD1, Pranita D. Tamma, MD, MHS2, Kathryn Dzintars, PharmD1, Edina Avdic, MBA, PharmD, BCPS AQ-ID3 and Sara Cosgrove, MD, MS, FIDSA, FSHEA4, (1)Department of Pharmacy, Johns Hopkins Hospital, Baltimore, MD, (2)Department of Pediatrics, Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, MD, (3)Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, (4)Department of Medicine, Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, MD


    T. Smith, None

    P. D. Tamma, None

    K. Dzintars, None

    E. Avdic, None

    S. Cosgrove, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.